Hong Kong · Delayed Price · Currency is HKD Achilles Therapeutics Statistics
Total Valuation
HKG:2592 has a market cap or net worth of HKD 4.25 billion. The enterprise value is 6.99 billion.
| Market Cap | 4.25B |
| Enterprise Value | 6.99B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:2592 has 838.89 million shares outstanding.
| Current Share Class | 838.89M |
| Shares Outstanding | 838.89M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 44.13% |
| Owned by Institutions (%) | n/a |
| Float | 276.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 54.76 |
| PB Ratio | -1.56 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.07 |
| EV / Sales | 89.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -33.71 |
Financial Position
The company has a current ratio of 0.10
| Current Ratio | 0.10 |
| Quick Ratio | 0.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -14.50 |
| Interest Coverage | -1,378.63 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -44.38% |
| Return on Invested Capital (ROIC) | -48.79% |
| Return on Capital Employed (ROCE) | 10.59% |
| Revenue Per Employee | 1.52M |
| Profits Per Employee | -15.10M |
| Employee Count | 51 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HKG:2592 has paid 6.47 million in taxes.
| Income Tax | 6.47M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 34.19 |
| Average Volume (20 Days) | 652,530 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:2592 had revenue of HKD 77.68 million and -769.99 million in losses. Loss per share was -1.62.
| Revenue | 77.68M |
| Gross Profit | 77.68M |
| Operating Income | -289.13M |
| Pretax Income | -763.52M |
| Net Income | -769.99M |
| EBITDA | -282.36M |
| EBIT | -289.13M |
| Loss Per Share | -1.62 |
Balance Sheet
The company has 270.79 million in cash and 3.00 billion in debt, giving a net cash position of -2.73 billion or -3.26 per share.
| Cash & Cash Equivalents | 270.79M |
| Total Debt | 3.00B |
| Net Cash | -2.73B |
| Net Cash Per Share | -3.26 |
| Equity (Book Value) | -2.73B |
| Book Value Per Share | -5.74 |
| Working Capital | -2.75B |
Cash Flow
In the last 12 months, operating cash flow was -206.01 million and capital expenditures -1.20 million, giving a free cash flow of -207.21 million.
| Operating Cash Flow | -206.01M |
| Capital Expenditures | -1.20M |
| Free Cash Flow | -207.21M |
| FCF Per Share | -0.25 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -372.23% |
| Pretax Margin | -982.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:2592 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -18.10% |
| FCF Yield | -4.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HKG:2592 has an Altman Z-Score of -25.48 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -25.48 |
| Piotroski F-Score | 1 |